Working… Menu

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02857998
Recruitment Status : Recruiting
First Posted : August 5, 2016
Last Update Posted : February 27, 2020
Information provided by (Responsible Party):
Hutchison Medipharma Limited

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021